Medicvision AI Signs Global MOUs to Advance Ophthalmic Innovation

MELBOURNE, AUSTRALIA / TAIPEI, TAIWAN – Medicvision AI Limited (MVA) is proud to announce a transformative leap forward in ophthalmic innovation following the successful Taiwan–Australia Ophthalmology Symposium held on February 10, 2026.

The symposium featured distinguished speakers including Keynote Presenter Professor Keith Martin, Managing Director of the Centre for Eye Research Australia (CERA), Professor Guei-Sheung (Rick) Liu from CERA, and Dr. Ta-Ching Chen from National Taiwan University Hospital. Their insights into cutting-edge research underscored the growing role of gene therapy and artificial intelligence (AI) in developing next-generation treatments for Inherited Retinal Diseases (IRDs), devastating genetic disorders that cause progressive vision loss.

We were also honored to welcome Mr. Robert Fergusson, Representative of Australia to Taiwan, whose presence strengthened the international spirit of the event.

Figure 1: Group photo of representatives from MVA, CERA, and Winston following the signing ceremony. From left to right: Dr. Stanley Chang, Chairman of Medigen; Mr. Jitto Arulampalam, Chairman of MVA; Dr. Sen-Tien Tsai, Chairman of Winston; Professor Keith Martin, Managing Director of CERA; and Mr. Robert Fergusson, Representative of Australia to Taiwan.

A key milestone from the symposium was the signing of a Memorandum of Understanding (MOU) between Medicvision AI Limited (MVA) and CERA.

This collaboration will combine CERA’s RNA Base Editing Platform with Medicvision’s strategic vision to accelerate the development of innovative therapies for IRDs, with the aim of bringing hope to patients and families affected by these conditions.

In addition, MVA formalized a strategic partnership with Winston Medical Supply Co., Ltd., committing both teams to jointly support the development and commercialization of ophthalmic pharmaceuticals. Winston will contribute product, technical, and regulatory expertise, while Medicvision will drive market evaluation, regulatory affairs, and commercialization efforts, establishing a solid foundation for future growth.

About Medicvision AI Limited Medicvision AI Limited is an Australian-based biotechnology firm specializing in the research, development, and commercialization of ophthalmic diagnostics and treatments. We integrate Artificial Intelligence and Gene Therapy to provide clinical solutions for complex eye diseases, ensuring a brighter future for patients worldwide.

→ View Press Release: Taiwan–Australia Ophthalmology Innovation Symposium

https://www.ctee.com.tw/news/20260211700032-430504